MeiraGTx Holdings plc
$10.53
▲
0.99%
2026-04-21 08:08:01
www.meiragtx.com
NMS: MGTX
Explore MeiraGTx Holdings plc stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$857.63 M
Current Price
$10.53
52W High / Low
$11.85 / $4.55
Stock P/E
—
Book Value
$-0.07
Dividend Yield
—
ROCE
-86.95%
ROE
-3.68%
Face Value
—
EPS
$-1.42
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
400
Beta
1.28
Debt / Equity
-15.31
Current Ratio
0.75
Quick Ratio
0.75
Forward P/E
-13.49
Price / Sales
8.98
Enterprise Value
$753.33 M
EV / EBITDA
-8.06
EV / Revenue
9.26
Rating
Strong Buy
Target Price
$26
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Recursion Pharmaceuticals, Inc. | $3.69 | — | $1.95 B | — | -48.86% | -59.54% | $7.18 / $2.8 | $2.14 |
| 2. | Alumis Inc. | $24.71 | — | $3.18 B | — | -134.01% | -86.68% | $30.6 / $2.76 | $2.88 |
| 3. | Codexis, Inc. | $2.62 | — | $235.35 M | — | -31.3% | -74.88% | $3.87 / $0.96 | $0.56 |
| 4. | CollPlant Biotechnologies Ltd. | $0.37 | — | $5.15 M | — | -141.54% | -1.18% | $4.98 / $0.27 | $0.47 |
| 5. | Cocrystal Pharma, Inc. | $1.51 | — | $20.82 M | — | -120.22% | -1.11% | $2.67 / $0.86 | $0.46 |
| 6. | NRx Pharmaceuticals, Inc. | $3.2 | — | $105.82 M | — | 103.85% | 146.18% | $3.84 / $1.62 | $-0.5 |
| 7. | Nektar Therapeutics | $100.35 | — | $2.87 B | — | -57.64% | -2.18% | $109 / $7.99 | $4.41 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 75.36 M | 0.41 M | 3.69 M | 1.93 M | 21.39 M | — |
| Operating Profit | 26.47 M | -46.05 M | -44.79 M | -41.6 M | -31.49 M | — |
| Net Profit | 15.09 M | -50.51 M | -38.8 M | -39.98 M | -39.4 M | — |
| EPS in Rs | 0.19 | -0.62 | -0.48 | -0.49 | -0.48 | -0.55 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 81.39 M | 33.28 M | 14.02 M | 15.92 M |
| Operating Profit | -105.97 M | -164.21 M | -137.06 M | -116.36 M |
| Net Profit | -114.2 M | -147.79 M | -84.03 M | -129.62 M |
| EPS in Rs | -1.4 | -1.81 | -1.03 | -1.59 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 244.43 M | 269.75 M | 326.74 M | 318.24 M |
| Total Liabilities | 250.22 M | 201.92 M | 188.57 M | 200.5 M |
| Equity | -5.79 M | 67.83 M | 138.18 M | 117.74 M |
| Current Assets | 91.76 M | 123.52 M | 159.62 M | 154.34 M |
| Current Liabilities | 122.56 M | 60.78 M | 67.08 M | 82.07 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -46.36 M | -104.5 M | -105.36 M | -73.1 M |
| Investing CF | -4.11 M | 23.48 M | 34.03 M | -44.96 M |
| Financing CF | 12.27 M | 54.53 M | 84.02 M | 95.2 M |
| Free CF | -50.59 M | -109.45 M | -125.54 M | -118.06 M |
| Capex | -4.24 M | -4.96 M | -20.17 M | -44.96 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 137.42% | -11.95% | — | — |
| Earnings Growth % | -75.89% | 35.17% | — | — |
| Profit Margin % | -444.1% | -599.46% | -814.16% | — |
| Operating Margin % | -493.44% | -977.82% | -730.87% | — |
| Gross Margin % | 28.51% | 100% | — | — |
| EBITDA Margin % | -366.11% | -407.06% | -729.06% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.